Advertisement

Advertisement

MNKD Stock Latest News

MannKind Prepares Shelf Registration for Potential Stock Offering

Company AnnouncementsMannKind Prepares Shelf Registration for Potential Stock Offering

MannKind price target lowered to $13 from $14 at Wells Fargo

PremiumThe Fly

MannKind price target lowered to $13 from $14 at Wells Fargo

19d ago

MannKind reports Q2 EPS (6c), consensus 2c

PremiumThe Fly

MannKind reports Q2 EPS (6c), consensus 2c

20d ago

MNKD Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

MNKD Earnings Report this Week: Is It a Buy, Ahead of Earnings?

22d ago

MannKind price target raised to $14 from $11 at Wells Fargo

PremiumThe Fly

MannKind price target raised to $14 from $11 at Wells Fargo

26d ago

MannKind reports ‘positive’ Phase 1b INFLO-1 results

PremiumThe FlyMannKind reports ‘positive’ Phase 1b INFLO-1 results

27d ago

MannKind Raises $50 Million in Private Placement

Company Announcements

MannKind Raises $50 Million in Private Placement

1M ago

MannKind announces FDA approval of Furoscix ReadyFlow

The Fly

MannKind announces FDA approval of Furoscix ReadyFlow

1M ago

MannKind announces $50M private placement

PremiumThe Fly

MannKind announces $50M private placement

1M ago

MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright

PremiumThe Fly

MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright

1M ago

MannKind’s MNKD-201 Trial: A New Inhaled Bet on Idiopathic Pulmonary Fibrosis

PremiumCompany Announcements

MannKind’s MNKD-201 Trial: A New Inhaled Bet on Idiopathic Pulmonary Fibrosis

1M ago

MannKind’s Inhaled IPF Drug Reaches Key Milestone, Setting Up the Next Move for MNKD

PremiumCompany Announcements

MannKind’s Inhaled IPF Drug Reaches Key Milestone, Setting Up the Next Move for MNKD

1M ago

MannKind announces milestones in development of nintedanib DPI for IPF

PremiumThe FlyMannKind announces milestones in development of nintedanib DPI for IPF

3M ago

MannKind Gains FDA Approval for Afrezza Pediatric Use

Company Announcements

MannKind Gains FDA Approval for Afrezza Pediatric Use

3M ago

MannKind price target raised to $11 from $10 at Wells Fargo

The Fly

MannKind price target raised to $11 from $10 at Wells Fargo

3M ago

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

PremiumThe Fly

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

3M ago

MannKind Released From Major Afrezza Trial Obligation

PremiumCompany Announcements

MannKind Released From Major Afrezza Trial Obligation

3M ago

MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles

PremiumCompany Announcements

MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles

3M ago

MannKind Leans Into Growth Amid Earnings Volatility

PremiumCompany Announcements

MannKind Leans Into Growth Amid Earnings Volatility

4M ago

MannKind price target lowered to $7 from $8 at Mizuho

PremiumThe FlyMannKind price target lowered to $7 from $8 at Mizuho

4M ago

MannKind price target raised to $10 from $8 at H.C. Wainwright

The Fly

MannKind price target raised to $10 from $8 at H.C. Wainwright

4M ago

MannKind price target raised to $10 from $8 at Wells Fargo

The Fly

MannKind price target raised to $10 from $8 at Wells Fargo

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >